Forecast

There is no analyst data available for this company.

News Go to news feed

WuXi XDC Cayman: major shareholder places shares to raise capital – stock falls

A major shareholder of WuXi XDC Cayman, STA Pharmaceutical Hongkong, placed 53.5 million shares at HK$73.23 each, apparently aiming to raise up to US$500 million. The news came with a substantial discount to the previous close and triggered a price drop of about 2.6% to HK$75.25. There was also profit-taking after WuXi’s strong half-year results. » More on de.investing.com
WuXi XDC posts first-half profit above RMB 1 billion — shares rise about 15%

WuXi XDC reported H1 2026 revenue of RMB 3.7 billion (+37% year‑on‑year) and an adjusted net profit of over RMB 1 billion. Gross margin improved to 37% and order backlog rose to over USD 2 billion, including around USD 120 million of commercial orders. The stock climbed 14.8% to USD 80.15. Management reaffirmed the full-year guidance (consolidated currency‑adjusted revenue growth ~30%, standalone ≥35%) and highlighted effects from the ramp‑up of the new Singapore site and integration costs related to BioDLink. » More on de.investing.com
WuXi XDC rises almost 12% after strong H1 results

WuXi XDC reported H1 2026 revenue of RMB 3.701 billion (+37% yoy) and an adjusted net profit attributable to shareholders of about RMB 1.027 billion (+37.4%). Gross margin improved to 37.0% and management cited the integration of BioDlink, the expansion of the global production network (including commercial production in Singapore) and the further development of its own technology platforms as drivers of structural growth. The stock then climbed roughly 12% to HK$78. » More on de.investing.com

Financials

In the last quarter, WuXi XDC Cayman Inc had revenue of €470.77M and net profit of €104.04M

(EUR)	Jun 2026	YoY
Revenue	470.77M	-
Gross profit	174.42M	-
Net profit	104.04M	-
EBITDA	151.95M	-

Fundamentals

Metric	Value
Market capitalization	€10.15B
Number of shares	1.27B
52-week high/low	€9.39 - €4.78
Dividends	No
Beta	-0.78
P/E ratio	51.31
PEG ratio	2.33
P/B ratio	6.97
P/S ratio	11.50

Company profile

WuXi XDC Cayman Inc. ist eine Investment-Holding, die als Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen in China, Nordamerika, Europa und international tätig ist. Es beschäftigt sich mit der Entdeckung, Forschung, Entwicklung und Herstellung von Antikörper-Wirkstoff-Konjugaten, Biokonjugaten, monoklonalen Antikörper-Zwischenprodukten und Nutzlast-Linkern in Verbindung mit Biokonjugaten. Das Unternehmen wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Wuxi, China. WuXi XDC Cayman Inc. ist als Tochtergesellschaft von WuXi Biologics (Cayman) Inc. tätig.